Amarantus Bioscience Holdings Inc (AMBS)

[Riskreturn168]

Absorbing Selling Pressure From Dominion and Weak Shareholders: At some point in the coming days this selling will recede and near term catalysts will have more favorable impact on our pps.

Diabetes Data: Gerald said a couple weeks ago he had data that would be released soon.

Eltoprazine (MJFF Grant?) Gerald keeps saying we will begin a Phase 2b clinical trial in the 2H 2014. I suspect we'll get grants for much of this cost.

Third Orphan Announcement: "Hearing" or Ischemic Heart?

Phenoguard: John told us a few months ago that this would be a source of revenue for 2014.

Unknowns?

AMBS has a lot of things in the hopper. Even though a LymPro partnership might be 2 to 4 months off, there are several things that could pop us up in the coming days and weeks.